Galliprant

Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). The two companies are partners on the canine drug Galliprant. What Happened The stock-for-stock deal is worth as much as $245...

A shareholder lawsuit was filed against Aratana Therapeutics Inc (NASDAQ: PETX) after the company’s announcement Monday that the release of Entyce, an appetite stimulant for dogs, would be delayed until late 2017. Aratana’s stock dropped about 19 percent after the news about Entyce...

Bruce Jackson of Lake Street assumes coverage of Aratana Therapeutics Inc (NASDAQ: PETX) with a Buy rating and $15 target price, saying twelve additional new products in the pipeline suggest the revenue growth can continue for the next several years. The analyst expects more than $200 million in...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) and Aratana Therapeutics Inc (NASDAQ: PETX) have come out with positive announcements that should cheer investors on Thursday. Aerie Pharma reported the successful 12-month interim safety results of Rocket 2, Aerie's second Phase 3 registration trial for...

The share price of Aratana Therapeutics Inc (NASDAQ: PETX) has declined 65.6 percent year-to-date, almost touching its 52-week low on November 19. Barclays’ Douglas D. Tsao has maintained an Overweight rating on the company, while lowering the price target from $30 to $15. Although the stock...